Unknown

Dataset Information

0

Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.


ABSTRACT: The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.

SUBMITTER: Marques J 

PROVIDER: S-EPMC5332526 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.

Marques Joana J   Valle-Delgado Juan José JJ   Urbán Patricia P   Baró Elisabet E   Prohens Rafel R   Mayor Alfredo A   Cisteró Pau P   Delves Michael M   Sinden Robert E RE   Grandfils Christian C   de Paz José L JL   García-Salcedo José A JA   Fernàndez-Busquets Xavier X  

Nanomedicine : nanotechnology, biology, and medicine 20161005 2


The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of n  ...[more]

Similar Datasets

| S-EPMC9846706 | biostudies-literature
| S-EPMC5700361 | biostudies-literature
| S-EPMC5323250 | biostudies-literature
| S-EPMC10373654 | biostudies-literature
| S-EPMC8188206 | biostudies-literature
| S-EPMC6395896 | biostudies-literature
| S-EPMC3845824 | biostudies-literature
| S-EPMC8095663 | biostudies-literature
| S-EPMC8708248 | biostudies-literature
| S-EPMC4656109 | biostudies-literature